Site Editor

Thomas Flaig, MD


Vadim S. Koshkin, MD, and Tanya Jindal, BS, BA, on Biomarkers to Predict Response to Enfortumab Vedotin-ejfv in Urothelial Carcinoma

Posted: Wednesday, March 8, 2023

Vadim S. Koshkin, MD, and Tanya Jindal, BS, BA, both of the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discuss the ramifications of new findings from the retrospective UNITE study. These results may potentially lead to better clinical decision-making on choosing patients with advanced urothelial carcinoma who might benefit from treatment with enfortumab vedotin.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.